Enfuvirtide biosimilar - Paras Biopharmaceuticals
Latest Information Update: 30 Oct 2021
At a glance
- Originator Paras Biopharmaceuticals Finland
- Class Antiretrovirals; Antivirals; Env gene products; Peptide fragments; Viral fusion proteins
- Mechanism of Action HIV fusion inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for research development in HIV-infections in Finland (Parenteral)
- 20 May 2015 Early research in HIV infections in Finland (Parenteral) (Paras pipeline, May 2015)